Anti-PD-1/PD-L1 therapy has also been shown to have a role in locally advanced NSCLC after chemo-radiotherapy, as well as in combination with chemotherapy in patients with small-cell lung cancer (SCLC). This evidence concerns the gene CD274 and non-small cell lung carcinoma.